Summary

Nucleic Acid Therapeutics Market – Scope of Report
TMR’s report on the global nucleic acid therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2024 to 2034. The report provides revenue of the global nucleic acid therapeutics market for the period 2018–2034, considering 2024 as the base year and 2034 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global nucleic acid therapeutics market from 2024 to 2034.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the nucleic acid therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global nucleic acid therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global nucleic acid therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global nucleic acid therapeutics market.

The report delves into the competitive landscape of the global nucleic acid therapeutics market. Key players operating in the global nucleic acid therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global nucleic acid therapeutics market profiled in this report.

Key Questions Answered in Global nucleic acid therapeutics Market Report
• What is the sales/revenue generated by nucleic acid therapeutics across all regions during the forecast period?
• What are the opportunities in the global nucleic acid therapeutics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2034?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Nucleic Acid Therapeutics Market – Research Objectives and Research Approach
The comprehensive report on the global nucleic acid therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global nucleic acid therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2034 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global nucleic acid therapeutics market.

ページTOPに戻る

Table of Contents

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Nucleic Acid Therapeutics Market
4. Market Overview
    4.1. Introduction
        4.1.1. Segment Definition
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, 2020-2034
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Pipeline Analysis
    5.2. Regulatory Scenario by Countries
    5.3. Technological Advancement
    5.4. Reimbursement Scenario
    5.5. PESTEL Analysis
    5.6. Porter’s Five Force Analysis
    5.7. Impact Analysis on Market
    5.8. Investment Scenario
    5.9. Unmet Needs in Current Treatment Landscape
6. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, By Product
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast By Product, 2020-2034
        6.3.1. Anti-Sense Oligonucleotides (ASO)
        6.3.2. RNA Interference (RNAi)
        6.3.3. RNA Aptamers
    6.4. Market Attractiveness By Product
7. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, By Indication
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast By Indication, 2020-2034
        7.3.1. Autoimmune Disorders
        7.3.2. Infectious Diseases
        7.3.3. Genetic Disorders
        7.3.4. Cancer
        7.3.5. Others
    7.4. Market Attractiveness By Indication
8. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, By End-user
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast By End-user, 2020-2034
        8.3.1. Hospitals
        8.3.2. Physicians’ Offices
        8.3.3. Others
    8.4. Market Attractiveness By End-user
9. Global Nucleic Acid Therapeutics Market Analysis and Forecasts, By Region
    9.1. Key Findings
    9.2. Market Value Forecast By Region
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness By Country/Region
10. North America Nucleic Acid Therapeutics Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast By Product, 2020-2034
        10.2.1. Anti-Sense Oligonucleotides (ASO)
        10.2.2. RNA Interference (RNAi)
        10.2.3. RNA Aptamers
    10.3. Market Value Forecast By Indication, 2020-2034
        10.3.1. Autoimmune Disorders
        10.3.2. Infectious Diseases
        10.3.3. Genetic Disorders
        10.3.4. Cancer
        10.3.5. Others
    10.4. Market Value Forecast By End-user, 2020-2034
        10.4.1. Hospitals
        10.4.2. Physicians’ Offices
        10.4.3. Others
    10.5. Market Value Forecast By Country, 2020-2034
        10.5.1. U.S.
        10.5.2. Canada
    10.6. Market Attractiveness Analysis
        10.6.1. By Product
        10.6.2. By Indication
        10.6.3. By End-user
        10.6.4. By Country
11. Europe Nucleic Acid Therapeutics Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast By Product, 2020-2034
        11.2.1. Anti-Sense Oligonucleotides (ASO)
        11.2.2. RNA Interference (RNAi)
        11.2.3. RNA Aptamers
    11.3. Market Value Forecast By Indication, 2020-2034
        11.3.1. Autoimmune Disorders
        11.3.2. Infectious Diseases
        11.3.3. Genetic Disorders
        11.3.4. Cancer
        11.3.5. Others
    11.4. Market Value Forecast By End-user, 2020-2034
        11.4.1. Hospitals
        11.4.2. Physicians’ Offices
        11.4.3. Others
    11.5. Market Value Forecast By Country/Sub-region, 2020-2034
        11.5.1. Germany
        11.5.2. U.K.
        11.5.3. France
        11.5.4. Italy
        11.5.5. Spain
        11.5.6. Rest of Europe
    11.6. Market Attractiveness Analysis
        11.6.1. By Product
        11.6.2. By Indication
        11.6.3. By End-user
        11.6.4. By Country/Sub-region
12. Asia Pacific Nucleic Acid Therapeutics Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast By Product, 2020-2034
        12.2.1. Anti-Sense Oligonucleotides (ASO)
        12.2.2. RNA Interference (RNAi)
        12.2.3. RNA Aptamers
    12.3. Market Value Forecast By Indication, 2020-2034
        12.3.1. Autoimmune Disorders
        12.3.2. Infectious Diseases
        12.3.3. Genetic Disorders
        12.3.4. Cancer
        12.3.5. Others
    12.4. Market Value Forecast By End-user, 2020-2034
        12.4.1. Hospitals
        12.4.2. Physicians’ Offices
        12.4.3. Others
    12.5. Market Value Forecast By Country/Sub-region, 2020-2034
        12.5.1. China
        12.5.2. India
        12.5.3. Japan
        12.5.4. Australia & New Zealand
        12.5.5. Rest of Asia Pacific
    12.6. Market Attractiveness Analysis
        12.6.1. By Product
        12.6.2. By Indication
        12.6.3. By End-user
        12.6.4. By Country/Sub-region
13. Latin America Nucleic Acid Therapeutics Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast By Product, 2020-2034
        13.2.1. Anti-Sense Oligonucleotides (ASO)
        13.2.2. RNA Interference (RNAi)
        13.2.3. RNA Aptamers
    13.3. Market Value Forecast By Indication, 2020-2034
        13.3.1. Autoimmune Disorders
        13.3.2. Infectious Diseases
        13.3.3. Genetic Disorders
        13.3.4. Cancer
        13.3.5. Others
    13.4. Market Value Forecast By End-user, 2020-2034
        13.4.1. Hospitals
        13.4.2. Physicians’ Offices
        13.4.3. Others
    13.5. Market Value Forecast By Country/Sub-region, 2020-2034
        13.5.1. Brazil
        13.5.2. Mexico
        13.5.3. Rest of Latin America
    13.6. Market Attractiveness Analysis
        13.6.1. By Product
        13.6.2. By Indication
        13.6.3. By End-user
        13.6.4. By Country/Sub-region
14. Middle East & Africa Nucleic Acid Therapeutics Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast By Product, 2020-2034
        14.2.1. Anti-Sense Oligonucleotides (ASO)
        14.2.2. RNA Interference (RNAi)
        14.2.3. RNA Aptamers
    14.3. Market Value Forecast By Indication, 2020-2034
        14.3.1. Autoimmune Disorders
        14.3.2. Infectious Diseases
        14.3.3. Genetic Disorders
        14.3.4. Cancer
        14.3.5. Others
    14.4. Market Value Forecast By End-user, 2020-2034
        14.4.1. Hospitals
        14.4.2. Physicians’ Offices
        14.4.3. Others
    14.5. Market Value Forecast By Country/Sub-region, 2020-2034
        14.5.1. GCC
        14.5.2. South Africa
        14.5.3. Rest of Middle East & Africa
    14.6. Market Attractiveness Analysis
        14.6.1. By Product
        14.6.2. By Indication
        14.6.3. By End-user
        14.6.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player - Competition Matrix (By Tier and Size of companies)
    15.2. Market Share Analysis By Company (2023)
    15.3. Company Profiles
        15.3.1. Alynylam Pharmaceutials, Inc.
            15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.1.2. Product Portfolio
            15.3.1.3. Financial Overview
            15.3.1.4. SWOT Analysis
            15.3.1.5. Strategic Overview
        15.3.2. BioNTech
            15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.2.2. Product Portfolio
            15.3.2.3. Financial Overview
            15.3.2.4. SWOT Analysis
            15.3.2.5. Strategic Overview
        15.3.3. Ionis Pharmaceuticals, Inc.
            15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.3.2. Product Portfolio
            15.3.3.3. Financial Overview
            15.3.3.4. SWOT Analysis
            15.3.3.5. Strategic Overview
        15.3.4. Moderna
            15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.4.2. Product Portfolio
            15.3.4.3. Financial Overview
            15.3.4.4. SWOT Analysis
            15.3.4.5. Strategic Overview
        15.3.5. Nippon Shinyaku
            15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.5.2. Product Portfolio
            15.3.5.3. Financial Overview
            15.3.5.4. SWOT Analysis
            15.3.5.5. Strategic Overview
        15.3.6. Novartis
            15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.6.2. Product Portfolio
            15.3.6.3. Financial Overview
            15.3.6.4. SWOT Analysis
            15.3.6.5. Strategic Overview
        15.3.7. Pfizer
            15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.7.2. Product Portfolio
            15.3.7.3. Financial Overview
            15.3.7.4. SWOT Analysis
            15.3.7.5. Strategic Overview
        15.3.8. Sarepta Therapeutics
            15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.8.2. Product Portfolio
            15.3.8.3. Financial Overview
            15.3.8.4. SWOT Analysis
            15.3.8.5. Strategic Overview
        15.3.9. Biogen Inc.
            15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.9.2. Product Portfolio
            15.3.9.3. Financial Overview
            15.3.9.4. SWOT Analysis
            15.3.9.5. Strategic Overview
        15.3.10. Genzyme Sanofi
            15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.10.2. Product Portfolio
            15.3.10.3. Financial Overview
            15.3.10.4. SWOT Analysis
            15.3.10.5. Strategic Overview
        15.3.11. Percheron Therapeutics Ltd.
            15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
            15.3.11.2. Product Portfolio
            15.3.11.3. Financial Overview
            15.3.11.4. SWOT Analysis
            15.3.11.5. Strategic Overview